(NASDAQ: ALZN) Alzamend Neuro's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 11.85%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 32.68%.
Alzamend Neuro's earnings in 2026 is -$9,096,700.On average, 3 Wall Street analysts forecast ALZN's earnings for 2027 to be -$5,168,349, with the lowest ALZN earnings forecast at -$4,965,669, and the highest ALZN earnings forecast at -$5,320,360.
In 2028, ALZN is forecast to generate -$4,282,347 in earnings, with the lowest earnings forecast at -$4,114,411 and the highest earnings forecast at -$4,408,298.